drugset / Trial / NCT05300672

Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)

NCT05300672

RandomizedParallel-groupOpen-labelTreatment

Summary

Fibrinogen replacement could prevent haemorrhagic complications in ischemic stroke patients with secondary post-rtPA hypofibrinogenemia

Timeline

Start
2022-02-08
Primary completion
2024-12-31
Completion
2025-05-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fibrinogen Concentrate Human Protein / enzyme biologic 2 g Intravenous